Stryker Corporation (NYSE:SYK) VP M Kathryn Fink sold 150 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $154.46, for a total transaction of $23,169.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Stryker Corporation (NYSE SYK) opened at $152.36 on Tuesday. Stryker Corporation has a 52-week low of $111.22 and a 52-week high of $160.62. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. The stock has a market cap of $58,332.41, a price-to-earnings ratio of 24.70, a price-to-earnings-growth ratio of 2.45 and a beta of 0.78.
Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. Stryker had a net margin of 14.67% and a return on equity of 24.11%. Stryker’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same period last year, the firm posted $1.39 EPS. equities analysts anticipate that Stryker Corporation will post 6.47 earnings per share for the current fiscal year.
Several brokerages have recently commented on SYK. Royal Bank Of Canada restated a “buy” rating and issued a $155.00 price objective on shares of Stryker in a report on Monday, October 2nd. BidaskClub upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. ValuEngine lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Friday. SunTrust Banks restated a “buy” rating and issued a $161.00 price objective on shares of Stryker in a report on Monday, October 2nd. Finally, Oppenheimer set a $156.00 target price on shares of Stryker and gave the stock a “hold” rating in a report on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $152.10.
Several large investors have recently modified their holdings of SYK. Acrospire Investment Management LLC acquired a new position in Stryker during the second quarter worth about $111,000. Motco grew its holdings in shares of Stryker by 50.7% during the second quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after buying an additional 278 shares in the last quarter. San Francisco Sentry Investment Group CA grew its holdings in shares of Stryker by 47.8% during the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after buying an additional 325 shares in the last quarter. Bruderman Asset Management LLC purchased a new stake in shares of Stryker during the second quarter worth about $150,000. Finally, James Investment Research Inc. purchased a new stake in shares of Stryker during the second quarter worth about $155,000. 74.97% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/05/stryker-corporation-syk-vp-m-kathryn-fink-sells-150-shares-of-stock.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.